ShapeTx: Shaping up RNA editing

Shape edits RNA in vivo by recruiting adenosine deaminases

With its RNAfix platform, Shape is developing therapeutics that are designed to edit RNA in vivo by hijacking an enzyme in the target cell that naturally converts one RNA base to another.

The company raised $35.5 million in a series A this month led by NEA and boasts a scientific advisory board that includes George Church and James Collins.

The advantage of in vivo RNA

Read the full 645 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE